We engrafted MV411 AML cells (with MLL-AF4 and FLT3-ITD mutation) and found that IOX5 or venetoclax treatment alone decreased leukemic burden and extended survival of the recipient mice (Fig. 8e–h). Here, KMT2A is linked to acute myeloid leukemia.